

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

NCT06863155

Status RECRUITING
Sponsor Fundación EPIC
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (4)

- Patients with Signed informed consent and
- Patients with ≥ 18 years old and
- Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and
- Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used

Exclusion (7)

- Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.
- Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).
- Patients treatment for restenosis or stent thrombosis.
- Patients presentation in cardiogenic shock or after cardiorespiratory arrest.
- Patients with allergy to any of the components of the stent to be used.
- ... and 2 more (see full listing online)

Locations (9 total)

Hospital General Universitario de Albacete, Albacete, Spain
Hospital Universitario San Juan de Alicante, Alicante, Spain
Hospital General Universitario de Merida, Badajoz, Spain
... and 6 more locations